Product Pipeline

Proprietary Programs

Portola scientists are recognized leaders in the fields of platelet biology and thrombosis. Working together for more than a decade, our scientific team was the first to clone the platelet ADP receptor P2Y12, the target of both Plavix® (clopidogrel) and our own ADP receptor antagonist, elinogrel. Our team was also instrumental in the discovery, development and commercialization of the leading GP IIb-IIIa inhibitor, INTEGRILIN® (eptifibatide).

We are currently developing two proprietary products in the area of thrombosis:

  • Betrixaban, a Phase 3-ready, long-acting, oral direct Factor Xa inhibitor that has best-in-class properties to address the global multi-billion hospital, specialty, and chronic care anticoagulant markets;
  • PRT064445, a universal Factor Xa inhibitor antidote that is a companion product to betrixaban

Despite recent progress in the development of drugs for autoimmune/inflammatory diseases such as rheumatoid arthritis, lupus, psoriasis and organ transplant, these diseases remain underserved by currently available agents. By 2020, the autoimmune/inflammatory market is projected to be more than $40 billion.

In the area of inflammation, our broad chemistry capability has led to the discovery of potent, oral specific inhibitors of Spleen Tyrosine Kinase (Syk) and Janus Kinase (JAK), as well as dual inhibitors of Syk and JAK. Syk plays a key role as a mediator in a number of important signaling pathways and cell types including B cells, macrophages, basophils and neutrophils. Therefore, Syk inhibition may be ideal for the management of chronic autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus and allergic asthma. In addition, Syk has been shown to be required for the survival of certain non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) tumors.

We are developing multiple molecules across multiple targets: